The collaboration between Genmab, a Danish biotech company, and US-based Abbvie entails the development of a string of molecules – which was recently cut a little shorter when Abbvie decided to discontinue the shared efforts on one candidate in particular.
Duohexabody-CD37 (Gen3009), a treatment candidate for B-cell malignancies that typically form in white blood cells and include most non-Hodgkin lymphomas, was developed using the Duohexabody technology platform, and is now left solely in Genmab’s charge.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
FDA fast-tracks Eli Lilly's obesity candidate
Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.
Jefferies spots weaknesses in GN
One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.
Bavarian initiates new arm of phase III Covid-19 vaccine trial
The first patient has already been dosed in the US, and the Danish vaccine maker is now expanding the study to include Denmark and Belgium.
Life science CEOs' paychecks decrease as markets decline
When the markets are down, everyone is in the same boat, in theory -- however, former Ambu CEO Lars Marcher warns boards against unduly rewarding CEOs by changing pre-existing share-based programs.
Fujifilm doubles bottom line in annual report
Despite a 12.5% cost increase compared to the preceding year, Fujifilm Diosynth Biotechnologies managed to increase its profit twofold in 2021/2022.
KLIFO is looking for QA Specialist/Senior QA Specialist, GCP and GVP for our Glostrup office 
Lab Manager 
Upstream Processing CMC Specialist 
Senior Director Translational Pharmacology 
Senior Project Manager 
Orifarm Healthcare Product Development PMO Director 
Product specialist 
Principal Scientist - Drug Metabolism & Pharmacokinetics 
Nordic Key Account Manager, Hollister & Dansac 
Pharmacovigilance & Regulatory Assistant with an interest in non-fiction 
Quality Assurance & Regulatory Affairs Manager 
Chief Business Officer 
Clinical Project Lead 
Experienced IT Business Solutions Manager for the Danish Medicines Agency 
Scientist Radiochemistry